UNITED STATES





SECURITIES AND EXCHANGE COMMISSION





Washington, D.C.  20549








FORM 8-K








CURRENT REPORT





PURSUANT TO SECTION 13 OR 15(d) OF THE


SECURITIES EXCHANGE ACT OF 1934





Date of report (Date of earliest event reported): January 30, 2018





PFIZER INC.


(Exact name of registrant as specified in its charter)





Delaware1-361913-5315170(State or other(Commission File(I.R.S. Employerjurisdiction of(Number)Identification No.)incorporation)








235 East 42nd Street10017New York, New York(Zip Code)


(Address of principal executive offices)








Registrant’s telephone number, including area code:


(212) 733-2323





Not Applicable


(Former name or former address, if changed since last report)





Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):





[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)





[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)





[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))





[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).





Emerging growth company    ☐





If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐











---







Item 2.02 Results of Operations and Financial Condition





On January 30, 2018 , Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year  2017 . A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.





The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.





Item 9.01 Financial Statements and Exhibits





(d)  Exhibits








Exhibit NumberExhibit DescriptionExhibit 99Press Release of Pfizer Inc. dated January 30, 2018, reportingPfizer’s financial results for fourth-quarter and full-year 2017.











---










EXHIBIT INDEXExhibit No.Description99Press Release of Pfizer Inc. datedJanuary 30, 2018, reporting Pfizer’s financialresults for fourth-quarter and full-year 2017.











---










SIGNATURE





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.








PFIZER INC.By:/s/ Margaret M. MaddenMargaret M. MaddenSenior Vice President and Corporate SecretaryChief Governance Counsel


Dated: January 30, 2018